Cytokine release syndrome (CRS) is a commonly observed adverse event in T cell engaging immunotherapies, particularly for TCEs, with IL-6 playing a pivotal role in the pathophysiology of CRS [46]. The gene discussed is IL6; the disease is congenital rubella syndrome.